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TO THE EDITOR
Autosomal recessive congenital ichthyo-
sis (ARCI) is a Mendelian disorder of
keratinization. LI patients are born as
erythrodermic ‘‘collodion’’ babies but
soon become covered with scales. The
most commonly mutated genes in ARCI
are Transglutaminase 1, Ichthyin, and
the Arachidonate Lipoxygenases 12b
and 3 (Russell et al., 1995; Jobard
et al., 2002; Fischer, 2009). Hyper-
keratosis (scaling) is a cardinal feature
of disorders of keratinization, which are
characterized by abnormal barrier
function. For example, Tgm1-null mice
die perinatally because of transepi-
dermal water loss after birth, but
when this skin is grafted onto nude
mice, they form scales similar to ARCI
patients (Kuramoto et al., 2002). The
epidermis is hyperproliferative, pro-
duces increased non-polar lipid, and
the cornified layer is thickened. This
scaling is the principle phenotype in
ARCI patients, and the time taken to
remove scale significantly affects their
quality of life. Oral retinoids, the
current treatment for ARCI, efficiently
reduces scale formation but are also
rarely associated with side effects,
some serious (Rood et al., 2007).
Therefore, there is a need to develop
new treatments for ARCI.
Current research on alternate ARCI
treatments is focused on gene therapy
(Choate et al., 1996), or enzyme replace-
ment therapy, adding recombinant Tgm1
to the skin (Aufenvenne et al., 2012). A
greater understanding of the common
molecular mechanisms that lead to hyper-
keratosis would facilitate the discovery of
more directed therapies to reduce scaling
in ARCI. Therefore, we investigated com-
mon gene expression changes in two
different rat epidermal keratinocyte ARCI
models, to identify the common net-
works of differentially expressed genes
that are required for hyperkeratosis and,
within these molecular networks, to iden-
tify new ‘‘drug-able’’ targets for the reduc-
tion of hyperkeratosis.
Two separate Arachidonate 12-lipoxy-
genase (Alox12b) short hairpin RNA
(shRNA)–knockdown (kd) rat epider-
mal keratinocyte lines (Supplementary
Figure S1a and S1b online) were com-
pared with an existing Tgm1 shRNA–kd
line (O’Shaughnessy et al., 2010). Both
Tgm1- and Alox12b-kd organotypic
cultures were hyperkeratotic (Figure 1a).
Comparison of Tgm1-kd with Alox12b-kd
cultures revealed a common increase in
keratin 1 expression, but keratin 10 reduc-
tion was observed only in Tgm1-kd
cultures (Figure 1a and Supplementary
Figure S1c online), suggesting both com-
mon and distinct programs of altered gene
expression in the two models. Prin-
cipal component analysis confirmed that,
although phenotypically similar, overall
gene expression differences were diver-
gent (Figure 1b and Supplementary Figure
S2 online). Despite these differences, we
identified 155 genes that were commonly
upregulated and 78 genes that were com-
monly downregulated in both Tgm1- and
Alox12b-kd keratinocyte cultures (Supple-
mentary Table S1 online). We identified
upregulated genes related to the positive
regulation of apoptosis and downregulated
genes related to protein phosphorylation
(Supplementary Figure S3 online).
The only significant network of inter-
related genes was related to the genes
involved in the positive regulation of
apoptosis, and within this network we
identified the p53 ubiquitin ligase
Mdm2 as an attractive candidate gene
to target in order to reduce hyperker-
atosis, as mice overexpressing Mdm2
display a hyperkeratotic epidermis in a
p53-independent manner (Alkhalaf
et al., 1999). Mdm2 upregulation in
both Tgm1- and Alox12b-kd cultures
was confirmed by quantitative reverse
transcriptase in real-time PCR (Figure 1c
and d). In organotypic culture, cytoplasmicAccepted article preview online 4 September 2013; published online 17 October 2013
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Mdm2 expression was increased and was
more widespread (Supplementary Figure
S4 online). This expression pattern was
mirrored in ARCI patients in whom Mdm2
was strongly upregulated in the spinous
layer in 7/7 samples, clearly colocalizing
with upregulated keratin 1 (Figure 1e). p53
expression was undetectable in these
cultures (not shown), and p63, which
Mdm2 can also degrade, was not reduced
in either kd culture (Supplementary
Figure S4 online). Akt upregulation causes
hyperkeratosis (Janes et al., 2004), and
Mdm2 activates Akt (Singh et al., 2013).
Consistent with this, serine-phosphory-
lated Akt (pAkt) was upregulated in both
kd organotypic cultures (Supplementary
Figure S4 online). Therefore, in ARCI, we
hypothesized that Mdm2 functioned
through a p53/p63-independent pathway
involving increased Akt phosphorylation
to cause hyperkeratosis.
Mdm2 overexpression alone in kera-
tinocytes did not result in either keratin
1 or pAkt upregulation (Figure 2a). We
therefore tested whether the inhibition
of upregulated Mdm2 in the diseased
state was sufficient to reduce hyperkera-
tosis. As Mdm2 is commonly upregu-
lated in cancer (Berger et al., 2004),
a number of Mdm2 inhibitors are cur-
rently in phase I clinical trials (Secchiero
et al., 2011) and therefore could be
rapidly adopted to treat ARCI. Nutlin-3
is a well-characterized and easily
available Mdm2 inhibitor, which acts
by preventing the interaction of Mdm2
with p53, as well as other protein targets
(Nicholson et al., 2012).
Treatment of Tgm1- and Alox12b-kd
cells with nutlin-3 reduced both keratin
1 and pAkt expression levels (Figure 2b).
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Figure 1. Keratin 1 and Mdm2 upregulation in ARCI models and patient samples. (a) Immunofluorescence of keratins 1 and 10 in scrambled (Scram) control,
Tgm1-kd organotypic cultures, and Alox12b-kd organotypic cultures. (b) Principal component analysis comparing gene expression patterns between scrambled
controls, Tgm1-kd cells, and Alox12b-kd cells. Divergence between Alox12b- and Tgm1-kd cells indicates different gene expression profiles. (c) Network of
gene–gene interactions of the commonly overexpressed genes involved in apoptosis; red genes are overexpressed in ARCI models. (d) Quantitative reverse
transcriptase in real-time PCR analysis of apoptosis genes in the three scrambled controls, two Tgm1-kd keratinocyte cultures, and two Alox12b-kd keratinocyte
cultures; error bars SD, *Po0.05 one-way analysis of variance. (e) Immunofluorescence of Mdm2 and keratin 1 in ARCI skin (3 of n¼ 7) and a normal control.
Bar¼50mm (a, e). ARCI, autosomal recessive congenital ichthyosis; kd, knockdown; siRNA, small interfering RNA.
G Youssef et al.
Mdm2 Upregulation in Autosomal Recessive Congenital Ichthyosis
www.jidonline.org 859
Mdm2 expression was increased—a
known effect of Nutlin-3 treatment
(Kranz and Dobbelstein, 2006)—
suggesting that Mdm2 function is being
inhibited in our ARCI models. Redu-
ction of keratin 1 and pAkt was also
seen in both Tgm1- and Alox12b-kd
cells transfected with an Mdm2
shRNA plasmid, suggesting that the
effect of nutlin-3 was Mdm2 specific
(Figure 2c). Nutlin-3 treatment changed
Mdm2 localization from cytoplasm to
nucleus (Figure 2d) and reduced hyper-
keratosis and proliferation in the kd
organotypic culture (Figure 2e).
Mdm2 is cytoplasmic in ARCI, not
nuclear, as is observed in skin cancer
(Berger et al., 2004), and therefore
it is likely that cytoplasmic Mdm2
distribution is functionally significant in
hyperkeratosis. It is possible that Mdm2
directly interacts with keratin 1, and
therefore it would be interesting to
determine the interacting partners of
Mdm2 in a barrier-disrupted situation
such as ARCI. Evidence for a potential
interaction between Mdm2 and keratin
1 comes from a proteomic screening for
Mdm2-interacting proteins in the pre-
sence and absence of nutlin-3, which
reveals an interaction between Mdm2,
keratins, and keratin-associated proteins
that is lost with nutlin-3 treatment
(Nicholson et al., 2012). Therefore, we
present a pathway critical to hyper-
keratosis in ARCI, and potentially other
hyperkeratotic diseases, which is modu-
lated by Mdm2-inhibiting drugs.
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Figure 2. The Mdm2 inhibitor nutlin-3 reduces hyperkeratosis in ARCI models. (a–c) Western blot of Mdm2, keratin 1, pSerAkt, and total Akt in (a) rat epidermal
keratinocytes overexpressing Mdm2, (b) Tgm1- and Alox12b-kd cells treated with nutlin-3, and (c) Tgm1- and Alox12b-kd cells expressing Mdm2 short hairpin
RNA. Gapdh is the loading control. (d) Mdm2 immunofluoresence in Tgm1- and Alox12-kd cells with and without nutlin-3 treatment. (e) Histology of scrambled
(Scram) control and kd cultures with or without nutlin-3 treatment. In addition, keratin 1 and proliferating cell nuclear antigen (PCNA) immunofluoresence with the
mean percentage of PCNA-positive nuclei in the basal layer ±SEM (*Po0.05 for comparison either with Scram or with and without nutlin-3 treatment, n¼2).
Bars¼ 10mm (d), 50mm (e). ARCI, autosomal recessive congenital ichthyosis; kd, knockdown; siRNA, small interfering RNA.
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In Vivo siRNA Targeting of CD28 Reduces UV-Induced
DNA Damage and Inflammation
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TO THE EDITOR
Exposure to UV radiation is the major
factor for the development of non-
melanoma skin cancer, including squa-
mous cell and basal cell carcinoma.
The initial event in UV carcinogenesis
upon photon absorption by DNA is the
formation of cyclobutane pyrimidine
dimers (CPDs), and to a lesser extent,
pyrimidine-pyrimidone 6,4-photopro-
ducts. When these photoproducts are
left unrepaired or misrepaired, they can
lead to mutations in critical genes
such as the tumor suppressor gene p53
(Benjamin et al., 2008). However, depen-
ding on the dose of UVB exposure
and the amount of DNA photoproducts,
damaged cells undergo apoptosis or
survive through cellular repair mecha-
nisms (Clydesdale et al., 2001; Schwarz
and Schwarz, 2009), preventing or
allowing mutations to be formed from
unrepaired photoproducts. UVB-induced
DNA damage also serves as a trigger
for immunosuppression via the secretion
of IL-10 and tumor necrosis factor-a,
inhibition of dendritic cell function and
induction of regulatory T cells (Tregs;
Schwarz and Schwarz, 2009, 2011).
Certain cytokines may increase the
repair of DNA damage by stimulating
nucleotide excision repair (NER). For
instance, exogenous administration of
IL-12 and IL-23 was able to abrogate
the immunosuppressive effect of UVR
through induction of NER (Cline and
Hanawalt, 2003; Schwarz and Schwarz,
2009). It has been demonstrated that
CD80/CD86–CD28/CD152 signaling
has an important role in the prevention
of UVB-induced immunosuppression
and tumor formation (Beissert et al.,
1999; Loser et al., 2005). However, the
individual role of CD28 has not been
investigated in short-term UV effects,
including DNA damage. Here, we have
targeted CD28 with small interfering
RNA (siRNA) to determine the role of
this signaling pathway in the preservation
of UVB-induced skin alterations.
Mice were exposed to 80 mJ cm2
UVB (a moderate dose, as previously
determined (Pflegerl et al., 2009) imme-
diately after CD28 siRNA or control
siRNA injection (Figure 1a), and skin
samples were collected at 1, 6, and
24 hours after UVB exposure for hema-
toxylin and eosin and immunohisto-
chemical thymine dimer staining. We
found similar number of thymine dimers
(a specific form of CPDs), positive cells
and sunburn cells (SBC), in the epider-
mis of CD28 siRNA- and control siRNA-
injected mice 1 and 6 hours after UVBAccepted article preview online 16 September 2013; published online 31 October 2013
Abbreviations: CPD, cyclobutane pyrimidine dimer; NER, nucleotide excision repair; Treg, regulatory T cell
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